I flagged in August that Lorecivivint could be a
worthy rival, but was told by the bias confirmers
that it would not cut the mustard, although I was
never given a good reason why.
They certainly have the jump on us timewise,
by about 2-3 years. P3 results due late this
year. Also it appears they have considerable
financial backing.
Lets hope FDA gives them considerably more
homework.
Lorecivivint, page-7
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |